Excellence in Engagement through Digital channels and New Technology

Sponsored by

Back to Results

Winner

Swixx Rare Disease Academy – The Premier Educational Resource for Healthcare Professionals (HCPs) in Central and Eastern Europe (CEE)

by Swixx BioPharma

Summary of work

Managing rare diseases presents unique challenges due to unspecific patient symptoms, limited number of experts included in their management, and the need for multidisciplinary collaboration. To support healthcare professionals (HCPs) across 20 Central and Eastern European (CEE) countries, Swixx BioPharma launched the Swixx Rare Disease Academy—a digital platform designed to centralize on-line educational resources and facilitate continuous learning and networking among HCPs.
Leveraging Swixx’s unique business model as a partner to multiple pharmaceutical companies, the Academy provides comprehensive resources on 15 rare diseases. The platform offers a range of digital engagement tools, including webinars, symptom screening tools, patient stories, and interactive content, tailored to the HCP community’s channel preferences. It enables seamless access to materials via any digital device and integrates features such as login-based participation and satisfaction surveys to enhance personalization and engagement.
Since its launch, the materials on the platform provided educational content to nearly 1,300 participants and over 600 HCPs registered on the platform 6 months after launch. Future efforts will focus on expanding personalized content, refining user experience, and enhancing regional outreach to establish the Academy as the premier digital hub for rare disease education in the CEE region.

Judges’ comments

“‘Swixx Rare Disease Academy’ is a unique and incredibly valuable platform seeking to address fragmentation in rare diseases, which is a major problem. The company’s core business model is in itself a compelling approach to solve this on a commercial basis, and the Rare Disease Academy is an excellent idea. The team is focused on continually improving user experience and, while in its early stages, the platform’s design, execution and success measures appear to be extremely strong.”